Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase EARLY_PHASE1 1Phase 4 1Phase 3 1Phase 1 1

Status

Active not recruiting 3Recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 3Thoracic 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 3Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 901Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 433Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Interventional × montelukast × Clear all
NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Janssen Research & Development, LLC

Phase 2 Active not recruiting
68 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04268498 2026-03-24

ADVANCE

University of Miami

Phase 2 Active not recruiting
310 enrolled
Plasma cell

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

University of Miami

Phase 2 Recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 15 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT05704049 2025-12-29

IZALCO

Sanofi

Phase 2 Active not recruiting
118 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡